A Review on Complications of the Prolonged Use of Proton Pump Inhibitors (PPIs) and Presenting a Case of Barrett’s Esophagus

Neeta Kumar¹, Neeru Gupta², Kishan Kumar Jani³,
Meenakshi Nagarkar⁴, Nimisha Upadhyay⁵

¹²Indian Council of Medical Research, New Delhi, India.
³Medical Officer, Municipal Corporation, Delhi, India.
⁴Physician at Family Health Clinic, Apollo Hospital, New Delhi, India.
⁵The Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), New Delhi, India.
DOI: https://doi.org/10.24321/2349.7181.201820

Abstract

Background: Gastroesophageal reflux disease (GERD) is the most common among gastric disorders and treated by antacids especially proton pump inhibitors (PPIs). Though symptoms are reported to be controlled by PPIs, however the complications like barrettes esophagus, Cancers at GE junction are not studied and reported extensively. In view of symptomatic relief, the long, non-supervised, over the counter medication use has increased. Safety of such long-term has been attempted with the review of available evidence and presentation of a case.

Aim: To update available literature on the long-term use of PPIs and possible mechanisms behind adverse events.

Materials and Methods: A case of Barrette’s esophagus was presented, with long-term use of PPIs. Detailed history taking of the case was done and another evidence synthesis was done on the effects of the long and short-term use of PPIs. The literature search using Medline, Scopus, Scholar on adverse effects of the use of PPIs was done which were language and date unrestricted.

Results: Studies report many adverse effects on short-term (up to 5 years of use, namely: clostridium associated diarrhea, bacterial peritonitis, cholecystitis, pyogenic liver, liver cirrhosis, pneumonia, esophageal inflammations, nocturnal breakthrough acid reflux, interstitial nephritis, drug interaction and nutritional deficiencies mainly of Vitamin B 12 and iron) and long-term use, namely: Concomitant dyspepsia, Barrettes esophagus, osteoporosis, dementia, hypomagnesia, cancers at GE junction.

Conclusion: The health care providers and community should be made cautious, larger cohort observational studies are also recommended for more evidence.

Keywords: Barrette's esophagus, GERD, Proton Pump Inhibitors

Background

Estimated Prevalence of Gastroesophageal Reflux Disease (GERD) is 18.1 to 27.8% in North-America, 8.8 to 25.9% in Europe, 2.5 to 7.8% in East Asia, 8.7 to 33.1% in the Middle East, 11.6% in Australia, and 23.0% in South America.¹ The proton pump inhibitors market is expected to register a compound annual growth rate (CAGR) of 5% during the forecast period of 2018-2023.² In India, there is lack of

Corresponding Author: Dr. Neeta Kumar, Indian Council of Medical Research, New Delhi, India.
E-mail Id: neetakumar50@gmail.com
Orcid Id: https://orcid.org/0000-0002-7518-5068
How to cite this article: Kumar N, Gupta N, Jani KK et al. A Review on Complications of the Prolonged Use of Proton Pump Inhibitors (PPIs) and Presenting a Case of Barrett’s Esophagus. J Adv Res Med 2018; 5(4): 14-24.

Copyright (c) 2018 Journal of Advanced Research in Medicine (P-ISSN:2394-7047 & E-ISSN:2349-7181)
figures on use of antacids specially Proton Pump Inhibitors (PPIs), yet it is estimated as 2nd top-grossing medicine prescribed as well as consumed over the counter medicine. PPIs with a total market share of 15.4 percent of prescriptions in the United States costing more than $10 billion US dollars. In India PPIs have been among the top 10 bestselling medicines for several years.  

**How Long the Use of PPI is safe?**

Cochrane reviews have reportedly found PPIs safe for short term use in hospital settings.  
One study finds PPIs more efficacious in Asians as compared to Europe and America. However, these reports have not followed observational cohort studies which are considered one of the best methods to study adverse effects of medications used in real-world settings. The case reported in this paper prompted us to explore and review the issue of safety with prolonged PPIs use. It was observed that there is dearth of literature with proper study designs. So, this article also highlights need of meta-analyses of existing studies and further studies to fill the gap in literature.

The publications reporting that PPIs are safe in long term use, define long term up to 12 months. It is accepted even in papers advocating PPIs safety that very long term use up to 3 years is with side effects like vitamin B12 deficiency. Though some papers report PPIs as gastro protective in management of GERD, there are strong evidences of it causing gastric atrophy and changing organism colonisation in stomach. The side effects become more evident with increasing period of use of PPI beyond one year. After emergence of evidence from field level experiences, nowadays it has become concern, “safety of duration of use of PPIs” which was earlier not thought of. PPIs were being considered as harmless no matter how long one consumes it.

We are presenting herein a case to narrate it further with compilation of evidences of potentially serious side effects (table 1 and 2) with prolonged use of PPIs. In view of plenty of evidences of adverse events like gastric atrophy beyond one year use, vitamin B12 deficiency beyond 3 years of use, some complications within 6 months of use, further studies in the form of long-term cohort observation, meta-analysis on specific conditions with review of available literature is recommended. Despite vast variety of opinion, rational use of PPI is surely warranted.

**Case Description**

This case is about 34 years old, vegetarian, nonalcoholic, nonsmoking male, who was healthy before 12 years when he first presented with hematemesis and pain in upper abdomen in the year 2006. First endoscopy revealed multi oesophageal ulcers with bleeding. There was no abnormal growth visible anywhere. Test for H. Pylori was positive. No significant family history of illness was present. He was treated with regimen of antibiotic, antacid-PPI, multivitamins and advised to continue with these medications for 5 more days on discharge. However, patient continued the use of PPIs for more than 10 years almost continuously (Pantoprazole 40 mg once a day), as he felt relieved from symptoms.

During last 2 years he developed progressive dysphasia. He again underwent endoscopy in July 2018 and was found having strictureing growth adjacent to lumen at gastroesophageal (GE) junction. The histopathology of this exophytic growth (figure 1) was reported as Barrett’s esophagus with low grade dysplasia. It was observed that endoscope was negotiable with maneuvering through irregular mass at GE junction with narrowing of lumen. Mucosa of fundus, body antrum, pylorus of stomach and duodenum was reported as normal.
The use of PPIs was first debated when it was reportedly found affecting anti-platelet function of clopidogrel in genotype CYPZC19.11 Thereafter many studies reported various adverse events. Table 1 and 2 are summarizing commonest side effects and other published experimental, observational case control studies, cohort, meta-analysis, case reports and reviews available on pub-med registered journals, scholar, using key words of "short term use of proton pump inhibitors/PPIs", long term use of proton pump inhibitors/PPIs, side effects and adverse effects of proton pump inhibitors/PPIs. Reports of adverse reactions with up to 5 years use are given in Table 1 and longer than 5 years are in Table 2.

**Table 1.** Short term use of PPI: adverse effect reported with/after up to 5 year’s use

| Side/adverse effect with short term use                        | Reference                                                                 |
|---------------------------------------------------------------|---------------------------------------------------------------------------|
| Rise in clostridium difficile associated diarrhea             | Am J Gastroenterology 200812, Am Journal of Gastroenterology 201213, Gut Liver 201614, Clin Infect Dis. 201515, Am J Gastroenterol 201216, Curr Opin Gastroenterol. 201217 |
| Enhanced spontaneous bacterial peritonitis (SBP) and complications of cirrhosis in PPI users | Gut 201618, Aliment Pharmacol Ther 201219, Eur J Intern Med 201620 |
| Small intestinal bacteria overgrowth during PPI therapy       | Clinical Gastroenterology and Hepatology, 201021, Clin Gastroenterol Hepatol 200722, Eur J Clin Invest 201123, Am J Gastroenterol 201524 |
| Increased risk of cholecystitis                               | Gut 201825                                                             |
| Liver abscess- cryptogenic liver abscess and pyogenic liver abscess, hepatitis | Aliment Pharmacol Ther 201526, Gastroenterology 201727 |
| Liver cirrhosis among PPI users                               | Eur J Clin Pharmacol 201728                                             |
| Pneumonia cases, more with PPI users                          | PLoS One, 201729, Annals of Neurology 201430, Ann Intern Med 200831, Medicine (Baltimore) 201532, JAMA 200433 |
| Esophageal inflammation, eosinophilia                        | Clin Infect Dis 201734, Aliment Pharmacol Ther 201235, JAMA Intern Med 201436, Respir Med 201537 |

**Table 2.** Drug interactions

| Nutritional Deficiencies - B12, Iron.                          | JAMA 201335, Gastroenterology 201736, Intern Med. 201837, Curr Ther Res Clin Exp. 201738, Geriatr Gerontol Int. 201739, Ned Tijdschr Geneesk. 201640, Circ J. 201541, Intern Med. 201442, Expert Rev Clin Pharmacol. 201343, Ther Adv Drug Saf. 201344, Dig Dis Sci. 201145, Am J Ther. 201246, Pain Physician 200947, Rev Prat. 200848, 49, Dig Dis Sci. 200250, Adv Nutr. 201851, Gut, 201752, Eur Rev Med Pharmacol Sci., 201553, Intern Med J. 201554, JAMA 201355, Georgian Med News 201256, Diabetes Care 201757, J Nutr Elder. 201058, Aliment Pharmacol Ther. 200859, J Am Med Dir Assoc. 200860, J Clin Epidemiol. 200461, Ann Pharmacother. 200262, Aliment Pharmacol Ther. 199963, Aliment Pharmacol Ther. 199964, J Intern Med. 199665, J Am Coll Nutr. 199466, Ann Intern Med. 199467 |

| Nocturnal breakthrough acid reflux                            | Aliment Pharmacol Ther 200068 |
| Interstitial Nephritis, Chronic Kidney disease                | Canadian Medical Association Journal 200969, Aliment Pharmacol Ther. 200770, CMAJ Open 201571, JAMA Intern Med. 201672, J Am Soc Nephrol. 201673, Dig Dis Sci. 201774, JAMA Intern Med. 201675, 76 |

**Table 1.**

| Side/adverse effect with short term use                          | Reference                                                                 |
|----------------------------------------------------------------|---------------------------------------------------------------------------|
| Increased risk of cholecystitis                                 | Gut 201825                                                             |
| Liver abscess- cryptogenic liver abscess and pyogenic liver abscess, hepatitis | Aliment Pharmacol Ther 201526, Gastroenterology 201727 |
| Liver cirrhosis among PPI users                                 | Eur J Clin Pharmacol 201728                                             |
| Pneumonia cases, more with PPI users                            | PLoS One, 201729, Annals of Neurology 201430, Ann Intern Med 200831, Medicine (Baltimore) 201532, JAMA 200433 |
| Esophageal inflammation, eosinophilia                          | Clin Infect Dis 201734, Aliment Pharmacol Ther 201235, JAMA Intern Med 201436, Respir Med 201537 |

**Table 2.**

| Nutritional Deficiencies - B12, Iron.                          | JAMA 201335, Gastroenterology 201736, Intern Med. 201837, Curr Ther Res Clin Exp. 201738, Geriatr Gerontol Int. 201739, Ned Tijdschr Geneesk. 201640, Circ J. 201541, Intern Med. 201442, Expert Rev Clin Pharmacol. 201343, Ther Adv Drug Saf. 201344, Dig Dis Sci. 201145, Am J Ther. 201246, Pain Physician 200947, Rev Prat. 200848, 49, Dig Dis Sci. 200250, Adv Nutr. 201851, Gut, 201752, Eur Rev Med Pharmacol Sci., 201553, Intern Med J. 201554, JAMA 201355, Georgian Med News 201256, Diabetes Care 201757, J Nutr Elder. 201058, Aliment Pharmacol Ther. 200859, J Am Med Dir Assoc. 200860, J Clin Epidemiol. 200461, Ann Pharmacother. 200262, Aliment Pharmacol Ther. 199963, Aliment Pharmacol Ther. 199964, J Intern Med. 199665, J Am Coll Nutr. 199466, Ann Intern Med. 199467 |
| Nocturnal breakthrough acid reflux                              | Aliment Pharmacol Ther 200068 |
| Interstitial Nephritis, Chronic Kidney disease                  | Canadian Medical Association Journal 200969, Aliment Pharmacol Ther. 200770, CMAJ Open 201571, JAMA Intern Med. 201672, J Am Soc Nephrol. 201673, Dig Dis Sci. 201774, JAMA Intern Med. 201675, 76 |
Table 2. Long term adverse effect reported with 10 year’s use of PPI

| Side/adverse effects of long-term PPI use                  | References                                                                 |
|-----------------------------------------------------------|---------------------------------------------------------------------------|
| Concomitant dyspepsia, stroke, suppression of acid reflux leading to Barrett's, ulcer deaths reduced but non-ulcer deaths increased. | Neurogastroenterol Motil. 201193, Digestion 201790, Am J Gastroenterol. 201791 |
| Osteoporosis, hip/bone fracture                           | JAMA 200692, Calciﬁ Tissue Int. 201493, www.fda.gov 2015100, Osteoporos Int. 201594, Bone 201195, Pharmacoepidemiol Drug Saf. 201096, Gastroenterology 201097 |
| Dementia                                                  | JAMA Neurol. 201698, J Am Geriatr Soc. 201799                              |
| Hypomagnesia                                              | www.fda.gov 2015100, Aliment Pharmacol Ther. 2012102, Am J Kidney Dis. 2015102, Mol Pharm. 2012103, PLoS One 2015104, Am J Kidney Dis. 2010105, Am J Kidney Dis. 2015106, PLoS Med. 2014107 |
| Gastro esophageal cancer/other cancers                    | JAMA 2017108, Eur J Gastroenterol Hepatol. 2005109, Aliment Pharmacol Ther. 2004110, Br J Cancer 2009111, Aliment Pharmacol Ther. 2018112, Am J Gastroenterol. 2008113, Front Pharmacol. 2018114, Gut 2018115, Aliment Pharmacol Ther. 2018116, Pharmacoepidemiol Drug Saf. 2009117, Int J Cancer 2016118, 119 |

Discussion

Possible cause of the reaction seen in the case presented here was explored and found published mechanism which says that the changes in GE Mucosa after prolong use of PPIs can happen as result from the removal of the low pH barrier between upper GI tract bacteria and the lower gut leading to bile salts acting as constant irritant to GE junction. Various bile acids (BA) may cause intestinal metaplasia, which is yet to be elucidated for more detailed mechanism. In vitro evidence suggests that the secondary BA, deoxycholic acid, and lithocholic acid, are more potent inducers of intestinal metaplasia. Secondary BA is formed by intestinal microbiota in the terminal ileum and the anaerobic bacteria in the colon, which are distal to the foregut and require a neutral pH environment. Secondary BA has poor solubility, and their inability to ionize at the gastric pH, largely prevents them from reaching the esophagus in sufficient quantities to induce metaplasia.

The effectiveness of PPIs in controlling acid-related symptoms has resulted in their widespread use. However, in such an environment, the majority of bile salts, most likely glycoconjugates, potentially, may ionize and mobilize upstream into the esophagus. Thus, patients on long-term PPI treatment, and with a dysfunctional lower esophageal sphincter, may be at increased risk for Barrett’s esophagus and esophageal adenocarcinoma.

Possible cause and role of hyper intake at Adrenal gland in the presented case should be subjected to further research and review as there is no precedent report observing increased uptake of FDG-18 by adrenal gland. However, adrenal gland is the choice of seat for metastasis from adenocarcinoma but it may be reactive hyperactive adrenal gland too, so needs to be regularly followed-up in such cases.

As antacids, oral PPIs are reported with greater efficacy than histamine H2-receptor antagonists for the initial and maintenance treatment of GERD. In addition, PPIs has been shown to improve the quality of life of patients with GERD and is associated with high levels of patient satisfaction with therapy. The Food and Drug Administration (FDA) approved indications for PPI uses are: duodenal ulcer, erosive esophagitis, GERD, and gastric ulcer. For duration, maximum 2 weeks use in one time (though may repeat after 4 months) is the recommended-on duration of use by FD;

The treatment of GERD with PPIs is reported to improve symptoms and health-related quality of life outcomes. GERD patients are reported developing histopathological changes such as Barrett’s esophagus, significant risk for esophageal adenocarcinoma however, treatment information with PPI uses are not taken into account in these reporting’s. The incidence of GERD has progressively increased in Western industrialized nations; incidence of esophageal adenocarcinoma is also rising. Adenocarcinoma was reported among 26 per 100,000 person-years among patients with previously diagnosed erosive esophagitis against quite lower - 2.79 per 100,000 person-years in the general population in a Danish study. PPIs came in use for management of erosive esophagitis since it proved to be better in comparisons with ranitidine, patients receiving pantoprazole 40 mg daily were significantly more likely to remain in remission (after 12 month’s use) than patients receiving ranitidine daily. On the duration for use there are few studies showing quite good safety too with prolonged use of PPIs. For example, two trials are there, reporting...
data for treatment with oral Pantoprazole for up to 3 years which reported only 4 of 111 patients having adverse events which were definitely related to Pantoprazole.\textsuperscript{19, 128} The another 10-years study (long term), in which maintenance therapy with Pantoprazole 40 mg to 160 mg daily was found well tolerated in patients with healed peptic ulcers or erosive Esophagitis.\textsuperscript{134, 136} These studies report that there were no increases in signs associated with an enhanced risk of gastric cancer, although fasting serum gastrin levels increased slightly after the second year of treatment. Of 536 patients originally enrolled in one long-term study, 99 patients were treated with Pantoprazole for at least 5 years, and 25 reported completing 10 years of treatment with no adverse event.\textsuperscript{127}

Majority studies show complete relief of GERD-related symptoms with PPIs in the patients with erosive reflux disease ERD and non-erosive reflux disease NERD but are of only 4 to 8 weeks is the duration of study.\textsuperscript{128}

The majority of patients with erosive esophagitis relapse when treatment is stopped (about 75 percent at one year).\textsuperscript{128} Relapse is markedly reduced to 20 to 25 percent by daily maintenance treatment with proton pump blockers.\textsuperscript{128} A report from Italy shows 40% Proton pump inhibitor resistance\textsuperscript{129} and high relapse rates after cessation of treatment.\textsuperscript{130} Mild disease relapses less often\textsuperscript{128}, so long term therapy by intermittent treatment may prove acceptable and more cost-effective than maintenance treatment. This strategy remains unexplored in trials and requires further study.\textsuperscript{141}

About the knowledge attitude and practices regarding long term safety of PPIs among doctors in India, a study on prescription pattern on the use of PPIs reported that fifty resident doctors responded to the questionnaire. Thirty-six percent reported prescribing acid suppressive drugs for majority of their patients and 12% prescribed them to almost all patients they attended. Acute gastritis was the most common indication for prescribing PPI/H2 blockers (50%). The majority of respondents (92%) regarded PPIs as their first choice in acid suppressive agents and 58% administered it through intravenous route. Knowledge about PPI related adverse effects was low. Similar situation is reported from their counterparts in developed countries.\textsuperscript{132}

The rise of about 456% by 1997 with PPI use is reported since its first introduction (Omeprazole) in the late 1980s.\textsuperscript{133} In the United Kingdom, the total number of prescriptions for PPIs in the ambulatory setting increased 10-fold between 1991 and 1995. USA Health data PPIs increased from 146 million in 2009 to 164 million in 2013 (the 8\textsuperscript{th} position on the list of the top therapeutic classes by prescriptions).\textsuperscript{134} Studies report pattern of use of PPI in different setups-on admission; 82.62%, during hospitalization; and 54.75%, at discharge; and incorrect indications for PPIs were found in 74.47%, 61.25%, and 80.24% of the cases, respectively.\textsuperscript{134} For PPIs the 1year unjustified costs, calculated with reference to the lowest prices, were estimated to be more than 2 million United States dollars, contributing to the increasing expenditures of the health care system.\textsuperscript{135}

There are studies reporting long term use of PPIs on barrettes however not many report developments of barrettes and histological complications during use of PPIs. Now it is considered that islands of squamous cell among barrettes mucosa, are not sign of recovery.\textsuperscript{136, 137} Despite some new adverse event confirmed with PPI uses like a mild increased risk of vitamin B12 deficiency and chronic kidney disease, and a moderate increase in the risk of rebound hyper secretion, small intestinal bacterial overgrowth, and enteric infections, including Clostridium difficile. PPI’s link with dementia and spontaneous bacterial peritonitis is not clear and requires further investigation.\textsuperscript{138} PPIs are not recommended in breast-feeding mothers.\textsuperscript{139} And caution is recommended in view of reports of asthma in children on antenatal use.\textsuperscript{140, 141}

PPI use significantly increased the presence of Streptococcaeae and Enterococcaeae, which are risk factors for C. difficile infection, and decreased that of Faecalibacterium, a commensal anti-inflammatory microorganism.\textsuperscript{142} Long-term PPI use has included: carcinoid formation; development of gastric adenocarcinoma (especially in patients with Helicobacter pylori infection); bacterial overgrowth; enteric infections; and malabsorption of fat, minerals, and vitamins.\textsuperscript{143} Vitamin B12 concentration may be decreased when gastric acid is markedly suppressed for prolonged periods (e.g. Zollinger-Ellison syndrome), PPIs appear to increase susceptibility to the bacterial enteropathogens: Salmonella, Campylobacter jejuni, invasive strains of Escherichia coli, vegetative cells of Clostridium difficile, Vibrio cholerae and Listeria by PPI use, with adjusted relative risk ranges of 4.2-8.3 (two studies); 3.5-11.7 (four studies); and 1.2-5.0 (17 of 27 studies) for the three respective organisms.\textsuperscript{144}

Conclusion

There is need to add advisory of potential harms with prolonged use of PPIs, so that its benefits are not surpassed by dangerous outcomes. There is need to generate retrospective cohort studies with various side effects reported in this paper, specially in carcinoma oesophagus cases to further define safety limits of duration of use of PPIs.

Declaration of Patient Consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship: None
Conflicts of Interest: None

References

1. Brands of Pantoprazole. Available from: http://www.drugsupdate.com/brand/showavailablebrands/99/17. Accessed on: August 25, 2018.

2. Proton Pump Inhibitors Market - Segmented by Drug and Geography - Growth, Trends, and Forecast (2018-2023). Available from: https://www.mordorintelligence.com/industry-reports/proton-pump-inhibitors-market. Accessed on: August 25, 2018.

3. Protonix. Available from: https://www.rxlist.com/protonix-drug/patient-images-side-effects.htm#missdose. Accessed on: August 29, 2018.

4. Leonardi Gi, McIntyre L, Sharma VK et al. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2004; 3: CD002094.

5. Pinto-Sanchez MI, Yuan Y, Bercik P et al. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev. 2017; 3: CD011194.

6. Van Pinxteren B, Numans ME, Bonis PA et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2001; 4: CD002095.

7. Leonardi Gi, Sharma VK, Howden CW. Proton pumps inhibitor therapy for peptic ulcer bleeding in Asia – a post hoc analysis. Cochrane Collaboration, 2005.

8. Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep 2010; 12(6): 448-57.

9. Desilets AR, Asal NJ, Duncan KC. Considerations for the use of proton-pump inhibitors in older adults. Consult Pharm 2012; 27(2): 114-20.

10. Post market Drug Safety Information for Patients and Providers. FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. USFDA. Retrieved on: 2015-11-03.

11. Depta JP, Lenzini PA, Lanfear DE et al. Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction. Pharmacogenomics J 2015; 15(1): 20-5.

12. Aseri M, Schroeder T, Kramer J et al. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 2008; 103(9): 2308-13.

13. Janarthanan S, Ditah I, Adler DG et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. The American Journal of Gastroenterology 2012; 107: 1001-10.

14. Ro Y, Eun CS, Kim HS et al. Risk of Clostridium difficile infection with the use of a proton pump inhibitor for stress ulcer prophylaxis in critically ill patients. Gut Liver 2016; 10(4): 581-6.

15. Freedberg DE, Lamoussé-Smith ES, Lightdale JR et al. Use of acid suppression medication is associated with risk for C. difficile infection in infants and children: a population-based study. Clin Infect Dis 2015; 61(6): 912-7.

16. Kwok CS, Arthur AK, Anibueze CI, et al. Risk of clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012; 107(7): 1011-9.

17. Abraham NS. Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol 2012; 28(6): 615-20.

18. Jackson MA, Goodrich JK, Maxan ME et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 2016; 65(5):: 749-56.

19. Bajaj JS, Ratliff SM, Heuman DM et al. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. Aliment Pharmacol Ther 2012; 36(9): 866-74.

20. Huang KW, Kuan YC, Luo JC et al. Impact of long-term gastric acid suppression on spontaneous bacterial peritonitis in patients with advanced decompensated liver cirrhosis. Eur J Intern Med 2016; 32: 91-5.

21. Lombardo L, Foti M, Ruggia O at al. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clinical Gastroenterology and Hepatology 2010; 8(6): 504-8.

22. Garcia Rodriguez LA, Ruígómez A, Panés J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 2007; 5(12): 1418-23.

23. Compare D, Pica L, Rocco A. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest 2011; 41(4): 380-6.

24. Masclee GM, Coloma PM, Kuipers EJ et al. Increased risk of microscopic colitis with use of proton pump inhibitors and non-steroidal anti-inflammatory drugs. Am J Gastroenterol 2015; 110(5): 749-59.

25. Chuang SC, Lin CC, Peng CY et al. Proton pump inhibitors increase the risk of cholecystitis: a population-based case-control study. Gut 2018.

26. Wang YP, Liu CJ, Chen TJ et al. Proton pump inhibitor use significantly increases the risk of cryptogenic liver abscess: a population-based study. Aliment Pharmacol Ther 2015; 41(11): 1175-81.

27. Tsai CF, Chen MH, Wang YP et al. Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population study. Gastroenterology 2017; 152(1): 134-41.
28. Lin HF, Liao KF, Chang CM et al. Correlation between proton pump inhibitors and risk of pyogenic liver abscess. *Eur J Clin Pharmacol* 2017; 73(8): 1019-25.

29. Arai N, Nakamizo T, Ihara H et al. Histamine H2-blocker and proton pump inhibitor use and the risk of pneumonia in acute stroke: a retrospective analysis on susceptible patients. *PLoS One* 2017; 12(1): e0169300.

30. Herzig SJ, Doughty C, Lahoti S et al. Acid-suppressive medication use in acute stroke and hospital-acquired pneumonia. *Annals of Neurology* 2014; 76 (5): 712-8.

31. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. *Ann Intern Med* 2008; 149(6): 391-8.

32. Ho SW, Hsieh MJ, Yang SF et al. Risk of stroke-associated pneumonia with acid-suppressive drugs: a population-based cohort study. *Medicine (Baltimore)* 2015; 94(29): e1227.

33. Laheij RJ, Sturkenboom MC, Hassing RJ et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. *JAMA* 2004; 292(16): 1955-60.

34. Kvistholm Jensen A, Simonsen J, Ethelberg S. Use of proton pump inhibitors and the risk of listeriosis: a nationwide registry-based case-control study. *Clin Infect Dis* 2017; 64(7): 845-51.

35. Bajaj JS, Ratlliff SM, Heuman DM et al. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. *Aliment Pharmacol Ther* 2012; 36(9): 866-74.

36. MacLaren R, Reynolds PM, Allen RR. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. *JAMA Intern Med* 2014; 174(4): 564-74.

37. Benson VS, Müllerová H, Vestbo J et al. Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease. *Respir Med* 2015; 109(9): 1147-54.

38. Fass R, Sampliner RE, Malagon IB et al. Failure of oesophageal acid control in candidates for Barrett’s oesophagus reversal on a very high dose of proton pump inhibitor. *Aliment Pharmacol Ther* 2000; 14(5): 597-602.

39. Ricketson Jeffrey, Kimel Gil, Spence James et al. Acute allergic interstitial nephritis after use of pantoprazole. *Canadian Medical Association Journal* 2009; 180(5): 535-8.

40. Sierra F, Suarez M, Rey M et al. Systematic review: Proton pump inhibitor-associated acute interstitial nephritis. *Aliment Pharmacol Ther* 2007; 26: 545-53.

41. Antoniou T, Macdonald EM, Hollands S et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: A population-based cohort study. *CMAJ Open* 2015; 3: E166-71.

42. Lazarus B, Chen Y, Wilson FP et al. Proton pump inhibitor use and the risk of chronic kidney disease. *JAMA Intern Med* 2016; 176: 238-46.

43. Xie Y, Rowe B, Li T et al. Proton pump inhibitors and risk of incident CKD and progression to ESRD. *J Am Soc Nephrol* 2016; 27(10): 3153-63.

44. Wijarnpreecha K, Thongprayoon C, Chedschai S et al. Associations of proton-pump inhibitors and H2 receptor antagonists with chronic kidney disease: a meta-analysis. *Dig Dis Sci* 2017; 62(10): 2821-7.

45. Lazarus B, Chen Y, Wilson FP et al. Proton pump inhibitor use and the risk of chronic kidney disease. *JAMA Intern Med* 2016; 176(2): 238-46.

46. de Francisco ALM, Varas J, Ramos R et al. Proton pump inhibitor usage and the risk of mortality in hemodialysis patients. *Kidney Int Rep* 2017; 3(2): 374-84.

47. Meyer UA. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. *European Journal of Gastroenterology & Hepatology* 1996; 8 (Suppl 1): S21-5.

48. Kwok CS. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. *Aliment Pharmacol Ther* 2010; 31(8): 810-23.

49. Chen CB, Lin M, Eurich DT et al. Safety of concomitant metformin and proton pump inhibitor use: a population retrospective cohort study. *Clin Ther* 2016; 38(6): 1392-400.

50. Tvingsholm SA, Dehlendorff C, Østerlind K et al. Proton pump inhibitor use and cancer mortality. *Int J Cancer* 2018; 143(6): 1315-26.

51. Lee J, Youn K, Choi NK et al. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. *J Gastroenterol* 2013; 48(9): 1016-22.

52. Chu MP, Hecht JR, Slamon D et al. Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013/LOGiC randomized clinical trial. *JAMA Oncol* 2017; 3(6): 767-73.

53. Mukherjee S, Jana T, Pan JJ. Adverse effects of proton pump inhibitors on platelet count: a case report and review of the literature. *Case Rep Gastrointest Med* 2018; 30: 4294805.

54. Madanick RD. Proton pump inhibitor side effects and drug interactions: much ado about nothing? *Cleve Clin J Med* 2011; 78(1): 39-49.

55. Lam JR, Schneider JL, Zhao W et al. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. *JAMA* 2013; 310(22): 2435-42.

56. Lam JR, Schneider JL, Quesenberry CP et al. Proton pump inhibitor and Histamine-2 receptor antagonist use and iron deficiency. *Gastroenterology* 2017; 152(4): 821-9.
74. Jung SB, Nagaraja V, Kapur A et al. Association between vitamin B12 deficiency and long-term use of acid-lowering agents: a systematic review and meta-analysis. *Intern Med J* 2015; 45(4): 409-16.

75. Lam JR, Schneider JL, Zhao W et al. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. *JAMA* 2013; 310(22): 2435-42.

76. Zharkova A, Orlovsky V. Correlation between long-term proton pump inhibitor use, homocysteine and lipoproteins serum concentrations in patients with comorbidity of ischemic heart disease and acid peptic disease. *Georgian Med News* 2012; 213: 22-6.

77. Long AN, Atwell CL, Yoo W et al. Vitamin B (12) deficiency associated with concomitant metformin and proton pump inhibitor use. *Diabetes Care* 2012; 35(12): e84.

78. Rozgony NR, Fang C, Kuczynska ML et al. Vitamin B(12) deficiency is linked with long-term use of proton pump inhibitors in institutionalized older adults: could a cyanocobalamin nasal spray be beneficial? *J Nutr Elder* 2010; 29(1): 87-99.

79. Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. *Aliment Pharmacol Ther* 2008; 27(11): 1110-21.

80. Dharmarajan TS, Kanagala MR, Murakonda P et al. Do acid-lowering agents affect vitamin B12 status in older adults? *J Am Med Dir Assoc* 2008; 9(3): 162-7.

81. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. *J Clin Epidemiol* 2004; 57(4): 422-8.

82. Ruscin JM, Page RL, Valuck RJ. Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton–pump inhibitor. *Ann Pharmacother* 2002; 36(5): 812-6.

83. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC et al. Atrophic gastritis during long-term omeprazole therapy affects serum vitamin B12 levels. *Aliment Pharmacol Ther* 1999; 13(10): 1343-6.

84. Sagar M, Jancewksa I, Ljungdahl A et al. Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment. *Aliment Pharmacol Ther* 1999; 13(4): 453-8.

85. Bellou A, Aimone-Gastin I, De Korwin JD et al. Cobalamin deficiency with megaloblastic anaemia in one patient under long-term omeprazole therapy. *J Intern Med* 1996; 240(3): 161-4.

86. Saltzman JR, Kemp JA, Golner BB et al. Effect of hypochlorhydria due to omeprazole treatment or atrophic gastritis on protein-bound vitamin B12 absorption. *J Am Coll Nutr* 1994; 13(6): 584-91.

87. Marcuard SP, Albernez L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). *Ann Intern Med* 1994; 120(3): 211-5.

88. Liang JF, Chen YT, Fuh JL et al. Proton pump inhibitor-
related headaches: a nationwide population-based case-crossover study in Taiwan. *Cephalalgia* 2015; 35(3): 203-10.

89. Wu JC, Lai LH, Chow DK et al. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease. *Neurogastroenterol Motil* 2011; 23(2): 155-60.

90. Shah R, Richardson P, Yu H et al. Gastric acid suppression is associated with an increased risk of adverse outcomes in inflammatory bowel disease. *Digestion* 2017; 95(3): 188-93.

91. Wang YF, Chen YT, Luo IC et al. Proton-pump inhibitor use and the risk of first-time ischemic stroke in the general population: a nationwide population-based study. *Am J Gastroenterol* 2017; 112(7): 1084-93.

92. Yang YX, Lewis JD, Epstein S et al. Long-term proton pump inhibitor therapy and risk of hip fracture. *JAMA* 2006; 296(24): 2947-53.

93. Ding J, Heller DA, Ahern FM et al. The relationship between proton pump inhibitor adherence and fracture risk in the elderly. *Calcif Tissue Int* 2014; 94(6): 597-607.

94. Freedberg DE, Haynes K, Denburg MR et al. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study. *Osteoporos Int* 2015; 26(10): 2501-7.

95. Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. *Bone* 2011; 48(4): 768-76.

96. McGowan B, Bennett K, Barry M. Prescribing of anti-osteoporotic therapies following the use of proton pump inhibitors in general practice. *Pharmacoeconomical Drug Saf* 2010; 19(7): 763-9.

97. Corley DA, Kubo A, Zhao W et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. *Gastroenterology* 2010; 139(1): 93-101.

98. Gomm W, von Holt K, Thomé F et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. *JAMA Neurol* 2016; 73(4): 410-6.

99. Ho SW, Teng YH, Yang SF et al. Association of Proton Pump Inhibitors Usage with Risk of Pneumonia in Dementia Patients. *J Am Geriatr Soc* 2017; 65(7): 1441-7.

100. Drug Safety and Availability – FDA. Drug Safety Communication: Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs). Available on: www.fda.gov. Accessed on: August 23, 2018.

101. Hess MW, Hoenderop JG, Bindels RJ et al. Systematic review: Hypomagnesaemia induced by proton pump inhibition. *Aliment Pharmacol Ther* 2012; 36: 405-13.

102. Kieboom BC, Kiefte-de Jong JC, Eijgelsheim M et al. Proton pump inhibitors and hypomagnesemia in the general population: A population-based cohort study. *Am J Kidney Dis* 2015; 66: 775-82.

103. Bai JP, Hausman E, Lionberger R et al. Modeling and simulation of the effect of proton pump inhibitors on magnesium homeostasis 1. Oral absorption of magnesium. *Mol Pharm* 2012; 9: 3495-505.

104. Nakashima A, Okhido I, Yokoyama K et al. Proton pump inhibitor use and magnesium concentrations in hemodialysis patients: A cross-sectional study. *PloS One* 2015; 10: e014365.

105. Hoorn EJ, van der Hoek J, de Man RA et al. A case series of proton pump inhibitor-induced hypomagnesemia. *Am J Kidney Dis* 2010; 56: 112-6.

106. Kieboom BC, Kiefte-de Jong JC, Eijgelsheim M et al. Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study. *Am J Kidney Dis* 2015; 66(5): 775-82.

107. Zipursky J, Macdonald EM, Hollands S et al. Proton pump inhibitors and hospitalization with hypomagnesemia: a population-based case-control study. *PLoS Med* 2014; 11(9): e1001736.

108. Chu MP, Hecht JR, Slamon D et al. Association of proton pump inhibitors and capetcitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013/LOGiC randomized clinical trial. *JAMA Oncol* 2017; 3(6): 767-73.

109. Murphy SJ, Dickey W, Hughes D et al. Surveillance for Barrett’s oesophagus: results from a programme in Northern Ireland. *Eur J Gastroenterol Hepatol* 2005; 17(10): 1029-35.

110. Jankowski J, Sharma P. Approaches to Barrett’s oesophagus treatment—the role of proton pump inhibitors and other interventions. *Aliment Pharmacol Ther* 2004; 19 Suppl 1: 54-9.

111. Poulsen AH, Christensen S, McLaughlin JK et al. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. *Br J Cancer* 2009; 100(9): 1503-7.

112. Tran KT, McMenamin ÚC, Hicks B et al. Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies. *Aliment Pharmacol Ther* 2018; 48(1): 55-64.

113. Van Soest EM, van Rossum LG, Dieleman JP et al. Proton pump inhibitors and the risk of colorectal cancer. *Am J Gastroenterol* 2008; 103(4): 966-73.

114. Peng YC, Lin CL, Hsu WY et al. Association between cholangiocarcinoma and proton pump inhibitors use: a nested case-control study. *Front Pharmacol.* 2018; 9: 718.

115. Cheung KS, Chan EW, Wong AYS et al. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. *Gut* 2018; 67(1): 28-35.

116. Waldum HL. Editorial: proton pumps inhibitors (PPIs) and primary liver cancer. *Aliment Pharmacol Ther.* 2018; 48(3): 380-1.
117. Chubak J, Boudreau DM, Rulyak SJ et al. Colorectal cancer risk in relation to use of acid suppressive medications. *Pharmacoepidemiol Drug Saf* 2009; 18(7): 540-4.
118. Chien LN, Huang YJ, Shao YH et al. Proton pump inhibitors and risk of perianpillary cancers: A nested case-control study. *Int J Cancer* 2016; 138(6): 1401-9.
119. Tamim H, Duranceau A, Chen LQ et al. Association between use of acid-suppressive drugs and risk of gastric cancer. A nested case-control study. *Drug Saf* 2008; 31(8): 675-84.
120. Jackson MA, Goodrich JK, Maxan ME et al. Proton pump inhibitors alter the composition of the gut microbiota. *Gut* 2016; 65(5): 749-56.
121. Alsalahi O, Dobrian AD. Proton Pump Inhibitors: The Culprit for Barrett’s Esophagus? *Front Oncol* 2014; 4: 23.
122. Nomura M, Tashiro N, Watanabe T et al. Association of symptoms of gastroesophageal reflux with metabolic syndrome parameters in patients with endocine disease. *Gastroenterol* 2014: 863206.
123. Proton Pump Inhibitors: U.S. Food and drug administration-approved indications and dosages for use in adults. Available from: https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/Downloads/ppi-adult-dosingchart.pdf. Accessed on: August 10, 2018.
124. Scholten T. Long-term management of gastroesophageal reflux disease with pantoprazole. *Ther Clin Risk Manag* 2007; 3(2): 231-43.
125. Spechler SJ, Goyal RK. Barrett’s esophagus. *N Engl J Med* 1986; 315(6): 362-71.
126. Vakil N, Talley NJ, Stolte M et al. Patterns of gastritis and the effect of eradicating Helicobacter pylori on gastro-oesophageal reflux disease in Western patients with non-ulcer dyspepsia. *Aliment Pharmacol Ther* 2006; 24(1): 55-63.
127. Suleiman K, Limas K, Hartmut H et al. Pantoprazole 20 mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux disease. *European Journal of Gastroenterology & Hepatology* 2005; 7(9): 935-41.
128. Dabrowski A, Štabuc B, Lazebnik L. Meta-analysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease - PAN-STAR. *Prz Gastroenterol*. 2018; 13(1): 6-15.
129. Cicala M, Emerenziani S, Guarino MP et al. Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease. *World J Gastroenterol* 2013; 19(39): 6529-35.
130. Mohamed AH, Hunt RH. The rationale of acid suppression in the treatment of acid-related disease. *Aliment Pharmacol Ther* 1994; 8 Suppl 1: 3-10.
131. Bardhan KD. Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy-a sideways glance. *J Biol Med* 1996; 69(3): 211-24.
132. Padhy BM, Bhaduria HS, Gupta YK. Attitude and Knowledge of Indian Emergency Care Residents towards Use of Proton Pump Inhibitors. *International Scholarly Research* 2014; 6.
133. Boath EH, Blenkinsopp A. The rise and rise of proton pump inhibitor drugs: patients’ perspectives. *Soc Sci Med* 1997; 45(10): 1571-9.
134. Scarpignato C, Gatta L, Zullo A et al. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. *BMC Med* 2016; 9-14(1): 179.
135. Malavade P, Hiremath S. Proton pump inhibitors: More indigestion than relief? *Indian Journal of Nephrology* 2017; 27(4): 249-57.
136. Wilkinson SP, Biddlestone L, Gore S et al. Regression of columnar-lined (Barrett’s) oesophagus with omeprazole 40 mg daily: results of 5 years of continuous therapy. *Aliment Pharmacol Ther* 1999; 13(9): 1205-9.
137. Wani S, Sampliner RE, Weston AP et al. Lack of predictors of normalization of oesophageal acid exposure in Barrett’s oesophagus. *Aliment Pharmacol Ther*. 2005; 22(7): 627-33.
138. Singh A, Cresci GA, Kirby DF. Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome. *Nutr Clin Pract* 2018; 33(5): 614-24.
139. Malavade P, Hiremath S. Proton pump inhibitors: More indigestion than relief? *Indian J Nephrol* 2017; 27: 249-57.
140. Andersen AB, Erichsen R, Farkas DK et al. Prenatal exposure to acid-suppressive drugs and the risk of childhood asthma: a population-based Danish cohort study. *Aliment Pharmacol Ther* 2012; 35(10): 1190-8.
141. Roulet L, Vernaz N, Giostra E et al. Adverse effects of proton pump inhibitors: should we worry about long-term exposure? *Rev Med Interne* 2012; 33(8): 439-45.
142. Naito Y, Kashiwagi K, Takagi T et al. Intestinal Dysbiosis Secondary to Proton-Pump Inhibitor Use. *Digestion* 2018; 97(2): 195-204.
143. Laine L, Ahnen D, McClain C et al. Potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. *Aliment Pharmacol Ther* 2000; 14(6): 651-68.
144. Bavishi C, Dupont HL. Systematic review: The uses of proton pump inhibitors and increased susceptibility to enteric infection. *Aliment. Pharmacol Ther* 2011; 34(11-12): 1269-81.
145. Cicala M, Emerenziani S, Guarino MP et al. Proton pumps inhibitor resistance, the real challenge in gastro-esophageal reflux disease. *World J Gastroenterol* 2013; 19(39): 6529-35.
146. Savarino E, Marabotto E, Zentilin P et al. A safety review of proton pump inhibitors to treat acid-related digestive diseases. *Expert Opin Drug Saf* 2018; 23: 1-10.

147. Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. *Dig Dis Sci* 2011; 56(4): 931-50.

148. Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. *Am J Med* 2009; 122(10): 896-90.

149. Ament PW, Dicola DB, James ME. Reducing adverse effects of proton pump inhibitors. *Am Fam Physician* 2012; 86(1): 66-70.

150. Cicala M, Emerenziani S, Guarino MP et al. M Proton pump inhibitor resistance, the real challenge in gastroesophageal reflux disease. *World J Gastroenterol* 2013; 19(39): 6529-35.

151. Carlo Calabrese, Anna Fabbri, Giulio Di Febo. Long-term management of GERD in the elderly with pantoprazole. *Clin Interv Aging* 200; 2(1): 85–92.

152. Zhong Li, Cong Wu, Ling Li et al. Effect of long-term proton pump inhibitor administration on gastric mucosal atrophy: A meta-analysis. *Saudi J Gastroenterol* 2017; 23(4): 222-228.

Date of Submission: 2018-10-13
Date of Acceptance: 2018-10-30